Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,529,566
  • Shares Outstanding, K 215,397
  • Annual Sales, $ 1,882 M
  • Annual Income, $ 109,490 K
  • 60-Month Beta 0.97
  • Price/Sales 7.90
  • Price/Cash Flow 71.80
  • Price/Book 6.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.54
  • Number of Estimates 2
  • High Estimate 0.69
  • Low Estimate 0.39
  • Prior Year 0.35
  • Growth Rate Est. (year over year) +54.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.16 +2.11%
on 01/03/20
91.52 -16.15%
on 12/26/19
-14.69 (-16.07%)
since 12/24/19
3-Month
75.16 +2.11%
on 01/03/20
96.79 -20.71%
on 12/11/19
-0.76 (-0.98%)
since 10/24/19
52-Week
72.00 +6.58%
on 09/27/19
96.79 -20.71%
on 12/11/19
-0.27 (-0.35%)
since 01/24/19

Most Recent Stories

More News
Incyte to Report Fourth Quarter and Year-End Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2019 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 13, 2020.

INCY : 76.74 (-1.92%)
Look for Shares of Incyte Corp to Potentially Rebound after Yesterday's 1.88% Sell Off

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.06 to a high of $80.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $80.05...

INCY : 76.74 (-1.92%)
SmarTrend Watching for Potential Rebound in Shares of Incyte Corp After 1.88% Loss

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.06 to a high of $80.25. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $80.05...

INCY : 76.74 (-1.92%)
Serine Threonine Protein Kinase Pim 3, Pipeline Review, H2 2019 - Incyte Corp, Jasco Pharmaceuticals, Novartic AG & Yakult Honsha Co. Ltd. - ResearchAndMarkets.com

The "Serine Threonine Protein Kinase Pim 3 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

INCY : 76.74 (-1.92%)
YKLTY : 27.0300 (+0.33%)
MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

XNCR : 34.33 (-4.67%)
INCY : 76.74 (-1.92%)
Incyte (INCY) Stock Sinks As Market Gains: What You Should Know

Incyte (INCY) closed at $76.53 in the latest trading session, marking a -0.79% move from the prior day.

INCY : 76.74 (-1.92%)
Incyte's Application for Pemigatinib Gets EMA's Validation

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy....

AGIO : 53.03 (-0.41%)
EBS : 56.02 (-3.60%)
INCY : 76.74 (-1.92%)
ALXN : 105.27 (-3.02%)
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

A low-key week for the biotech sector, with a few pipeline and regulatory updates.

LIFE : 5.90 (-0.34%)
INCY : 76.74 (-1.92%)
EXEL : 18.02 (-7.92%)
APLS : 41.30 (-2.34%)
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma

Incyte (Nasdaq:INCY) today announced the validation of the Company's Marketing Authorization Application (MAA) for pemigatinib for the treatment of adults with locally advanced or metastatic...

INCY : 76.74 (-1.92%)
Company News For Jan 6, 2020

Companies In The News Are: CANF, LW, INCY, NOVN

LW : 90.69 (-0.22%)
INCY : 76.74 (-1.92%)
NOVN : 0.68 (+0.97%)
CANF : 2.68 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade INCY with:

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 80.04
1st Resistance Point 78.39
Last Price 76.74
1st Support Level 75.46
2nd Support Level 74.18

See More

52-Week High 96.79
Fibonacci 61.8% 87.32
Fibonacci 50% 84.40
Fibonacci 38.2% 81.47
Last Price 76.74
52-Week Low 72.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar